Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Michael Haas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6745-7177; OpenAlex author ID A5029807838, A5112062019. Sources: OpenAlex.

Their work

Papers
52 (first author 9, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
103
Papers, trials and grants by year

2012: 2 papers · 2013: 8 papers · 2014: 6 papers · 2015: 2 papers · 2016: 3 papers · 2017: 7 papers · 2018: 3 papers · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 2 papers · 2023: 5 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 50 of 52

  1. Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic Cancer. Co-author DOI 10.3390/cells15060527↗
  2. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  3. Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Co-author DOI 10.1158/2159-8290.cd-23-1480↗
  4. The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Co-author DOI 10.3390/biom15030426↗
  5. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Last author DOI 10.1007/s12094-023-03323-1↗
  6. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
  7. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Last author DOI 10.1016/j.esmoop.2024.102944↗
  8. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
  9. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  10. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02295-x↗
  11. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Last author DOI 10.1159/000528722↗
  12. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Last author DOI 10.3390/curroncol30060436↗
  13. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  14. Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients. Co-author DOI 10.3390/diagnostics12081905↗
  15. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s12094-021-02620-x↗
  16. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Co-author DOI 10.1016/j.ejca.2020.12.029↗
  17. Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers13225732↗
  18. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  19. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  20. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  21. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… First author DOI 10.1038/s41416-020-01029-7↗
  22. POLE gene hotspot mutations in advanced pancreatic cancer. Co-author DOI 10.1007/s00432-018-2746-x↗
  23. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  24. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdy417↗
  25. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  26. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. First author DOI 10.1016/j.thromres.2017.06.021↗
  27. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2017.115↗
  28. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  29. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. Co-author DOI 10.1093/annonc/mdw564↗
  30. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational resea… Co-author DOI 10.1186/s12885-017-3376-4↗
  31. The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. First author DOI 10.3390/ijms18051094↗
  32. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. First author DOI 10.1016/j.pan.2016.03.016↗
  33. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and… First author DOI 10.1038/bjc.2016.355↗
  34. Safety of palliative chemotherapy in advanced pancreatic cancer. Co-author DOI 10.1080/14740338.2016.1177510↗
  35. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Co-author DOI 10.1007/s13277-014-2885-x↗
  36. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Last author DOI 10.3109/0284186x.2015.1034877↗
  37. ALK expression is absent in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-014-1774-4↗
  38. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK010… Co-author DOI 10.1016/j.ejca.2014.04.023↗
  39. Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. First author DOI 10.1038/bjc.2014.60↗
  40. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Co-author DOI 10.1159/000355821↗
  41. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  42. Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine. First author PMID 25398821↗
  43. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Co-author DOI 10.1002/ijc.28294↗
  44. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analys… Co-author DOI 10.1007/s00432-012-1371-3↗
  45. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00535-013-0767-4↗
  46. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2013.158↗
  47. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. First author DOI 10.1093/annonc/mdt239↗
  48. Translational Research in Pancreatic Cancer Co-author DOI 10.1097/mpa.0b013e31829629f6↗
  49. Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients. Co-author DOI 10.5414/cpp51067↗
  50. Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author PMID 23267159↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefan Hubert Boeck · 50 shared papers, 2012–2026 · strength 4.53
  2. Volker Heinemann · 49 shared papers, 2012–2026 · strength 4.46
  3. Steffen Ormanns · 28 shared papers, 2013–2025 · strength 2.56
  4. Stephan Krüger · 29 shared papers, 2014–2025 · strength 2.26
  5. Christoph Benedikt Westphalen · 20 shared papers, 2016–2024 · strength 2.04
  6. Klara Dorman · 8 shared papers, 2023–2026 · strength 1.35
  7. Jens Werner · 10 shared papers, 2016–2023 · strength 1.07
  8. Stefan Holdenrieder · 12 shared papers, 2013–2026 · strength 1.01
  9. Michael Guenther · 6 shared papers, 2018–2025 · strength 0.95
  10. Lena Weiss · 6 shared papers, 2023–2024 · strength 0.95
  11. Danmei Zhang · 6 shared papers, 2023–2024 · strength 0.92
  12. Jens Thomas Siveke · 9 shared papers, 2013–2024 · strength 0.82
  13. Julia V. Mayerle · 6 shared papers, 2020–2024 · strength 0.79
  14. Dirk Waldschmidt · 5 shared papers, 2015–2024 · strength 0.65
  15. Anke Reinacher‐Schick · 5 shared papers, 2018–2024 · strength 0.63
  16. Lisa Miller‐Phillips · 3 shared papers, 2022–2025 · strength 0.48
  17. Sai Agash Surendran · 2 shared papers, 2023–2025 · strength 0.44
  18. Michael Ståhl · 3 shared papers, 2021–2024 · strength 0.43
  19. Hannah Randeu · 2 shared papers, 2022–2026 · strength 0.42
  20. Jan Goesta D’Haese · 4 shared papers, 2020–2023 · strength 0.38
  21. Jen Jen Yeh · 2 shared papers, 2025 · strength 0.37
  22. Leonie Gebauer · 3 shared papers, 2020–2023 · strength 0.35
  23. Dominik Paul Modest · 7 shared papers, 2013–2017 · strength 0.33
  24. Kathrin Heinrich · 2 shared papers, 2023–2024 · strength 0.32
  25. Volker Kunzmann · 3 shared papers, 2018–2023 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.